NO20082768L - Levodopa prodroge mesylat, sammensetninger og anvendelser derav - Google Patents
Levodopa prodroge mesylat, sammensetninger og anvendelser deravInfo
- Publication number
- NO20082768L NO20082768L NO20082768A NO20082768A NO20082768L NO 20082768 L NO20082768 L NO 20082768L NO 20082768 A NO20082768 A NO 20082768A NO 20082768 A NO20082768 A NO 20082768A NO 20082768 L NO20082768 L NO 20082768L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- levodopa prodrug
- prodrug mesylate
- mesylate
- methods
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- BFGJJGIBNQKBIQ-YLCXCWDSSA-N [(2r)-1-[(2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoyl]oxypropan-2-yl] benzoate;methanesulfonic acid Chemical compound CS(O)(=O)=O.C([C@H](N)C(=O)OC[C@@H](C)OC(=O)C=1C=CC=CC=1)C1=CC=C(O)C(O)=C1 BFGJJGIBNQKBIQ-YLCXCWDSSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74187605P | 2005-12-05 | 2005-12-05 | |
| PCT/US2006/046273 WO2007067495A2 (en) | 2005-12-05 | 2006-12-04 | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082768L true NO20082768L (no) | 2008-06-24 |
Family
ID=38123406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082768A NO20082768L (no) | 2005-12-05 | 2008-06-16 | Levodopa prodroge mesylat, sammensetninger og anvendelser derav |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US7563821B2 (https=) |
| EP (1) | EP1959948B1 (https=) |
| JP (1) | JP5153641B2 (https=) |
| KR (1) | KR101396639B1 (https=) |
| CN (1) | CN101365439B (https=) |
| AU (1) | AU2006322051B2 (https=) |
| BR (1) | BRPI0619425A2 (https=) |
| CA (1) | CA2631643C (https=) |
| CY (1) | CY1113108T1 (https=) |
| DK (1) | DK1959948T3 (https=) |
| ES (1) | ES2391575T3 (https=) |
| IL (1) | IL191937A (https=) |
| NO (1) | NO20082768L (https=) |
| NZ (1) | NZ569485A (https=) |
| PL (1) | PL1959948T3 (https=) |
| PT (1) | PT1959948E (https=) |
| RU (1) | RU2429223C2 (https=) |
| TW (1) | TWI403493B (https=) |
| WO (1) | WO2007067495A2 (https=) |
| ZA (1) | ZA200805511B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2365580C2 (ru) * | 2004-06-04 | 2009-08-27 | Ксенопорт, Инк. | Пролекарства леводопа, композиции на их основе и их применения |
| US7323585B2 (en) | 2004-06-04 | 2008-01-29 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
| TWI403493B (zh) * | 2005-12-05 | 2013-08-01 | Xenoport Inc | 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途 |
| WO2008034087A2 (en) * | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
| US7829592B2 (en) | 2006-12-21 | 2010-11-09 | Xenoport, Inc. | Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| CA2673336A1 (en) * | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| US8802681B2 (en) | 2008-10-17 | 2014-08-12 | Signature Therapeutics, Inc. | Pharmaceutical compositions with attenuated release of phenolic opioids |
| US8399513B2 (en) * | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| CN102186804A (zh) * | 2008-10-20 | 2011-09-14 | 克塞诺波特公司 | 合成左旋多巴酯前药的方法 |
| US8784847B2 (en) * | 2009-04-17 | 2014-07-22 | Merz Pharma Gmbh & Co. Kgaa | Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate |
| BR112012005124B1 (pt) | 2009-09-08 | 2021-11-09 | Signature Therapeutics, Inc. | Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos |
| WO2011056240A2 (en) | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| AU2011222856B2 (en) | 2010-03-04 | 2015-10-15 | Orion Corporation | Use of levodopa, carbidopa and entacapone for treating Parkinson's disease |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| US9238020B2 (en) | 2010-04-21 | 2016-01-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug |
| US10150792B2 (en) | 2010-11-08 | 2018-12-11 | Synthonics, Inc. | Bismuth-containing compounds, coordination polymers, methods for modulating pharmacokinetic properties of biologically active agents, and methods for treating patients |
| EP2647619B1 (en) | 2010-12-02 | 2015-01-21 | Ono Pharmaceutical Co., Ltd. | Novel compound and medical use thereof |
| ES2584634T3 (es) | 2011-01-11 | 2016-09-28 | Signature Therapeutics, Inc. | Composiciones que comprenden un profármaco de oxicodona escindible enzimáticamente |
| WO2012096886A1 (en) | 2011-01-11 | 2012-07-19 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| AU2012225337B2 (en) | 2011-03-09 | 2016-04-28 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
| CA2853251A1 (en) * | 2011-10-24 | 2013-05-02 | Endo Pharmaceuticals Solutions Inc. | Implantable rasagiline compositions and methods of treatment thereof |
| US9575244B2 (en) | 2013-01-04 | 2017-02-21 | Bal Makund Dhar | Light guide apparatus and fabrication method thereof |
| FR3008411B1 (fr) | 2013-07-12 | 2015-07-03 | Servier Lab | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
| CN103554078B (zh) * | 2013-11-22 | 2016-03-02 | 浙江安赛生物科技有限公司 | 低级醛（c2-c10）丙二醇缩醛的合成方法 |
| RU2743347C2 (ru) | 2014-10-21 | 2021-02-17 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| AU2016258179B2 (en) | 2015-05-06 | 2021-07-01 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| MY190011A (en) | 2016-04-11 | 2022-03-22 | Univ Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| HRP20221279T1 (hr) | 2016-07-14 | 2022-12-23 | Crinetics Pharmaceuticals, Inc. | Modulatori somatostatina i njihove uporabe |
| WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| EP3849533A4 (en) | 2018-09-13 | 2022-06-22 | University of Canberra | PROCEDURE FOR INHIBITION |
| CA3107139C (en) * | 2018-09-21 | 2023-01-03 | Kashiv Biosciences, Llc | Extended release compositions comprising trihexyphenidyl |
| CN113015531A (zh) | 2018-11-15 | 2021-06-22 | 艾伯维公司 | 用于皮下施用的药物调配物 |
| EP3999509A4 (en) * | 2019-07-17 | 2023-07-19 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of somatostatin modulators |
| FI4210700T3 (fi) | 2020-09-09 | 2025-09-16 | Crinetics Pharmaceuticals Inc | Somatostatiinimodulaatorin formulaatioita |
| WO2022056360A1 (en) * | 2020-09-11 | 2022-03-17 | Synagile Corporation | Methods for continuous oral drug delivery |
| US12599578B2 (en) | 2021-03-09 | 2026-04-14 | Ensysce Biosciences Inc. | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof |
| MX2024003466A (es) | 2021-09-29 | 2024-06-04 | Ensysce Biosciences Inc | Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos. |
| CN116500162A (zh) * | 2023-04-27 | 2023-07-28 | 北京和合医学诊断技术股份有限公司 | 一种同时检测6种药物浓度的液相色谱-质谱分析方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962414A (en) | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3811444A (en) | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2336218C3 (de) | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| US3983138A (en) | 1973-09-25 | 1976-09-28 | Merck & Co., Inc. | Amino acid esters |
| US4038411A (en) | 1973-09-25 | 1977-07-26 | Merck & Co., Inc. | Antihypertensive amino acid esters |
| US3992518A (en) | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
| US4093709A (en) | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
| US4079038A (en) | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
| US4066747A (en) | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
| US4070347A (en) | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
| FR2365341A1 (fr) | 1976-09-28 | 1978-04-21 | Synthelabo | Derives de l'acide l-(phenyl-3 amino-2 propionyloxy)-2 acetique |
| US4180509A (en) * | 1977-07-01 | 1979-12-25 | Merrell Toraude Et Compagnie | α-Ethynyl tryptophanes |
| US4311706A (en) | 1980-01-22 | 1982-01-19 | Interx Research Corporation | Novel dopa/dopamine prodrugs |
| JPS5824547A (ja) | 1981-08-06 | 1983-02-14 | Nippon Zoki Pharmaceut Co Ltd | 新規アミノ酸誘導体 |
| US4914222A (en) | 1983-08-29 | 1990-04-03 | Merck & Co., Inc. | Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process |
| LU85757A1 (fr) | 1985-02-04 | 1986-09-02 | Univ Catholique Louvain | Derives nouveaux de la l-dopa,procedes pour leur preparation et compositions pharmaceutiques concernant de tels composes |
| US4663349A (en) | 1985-12-30 | 1987-05-05 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
| US4771073A (en) | 1985-12-30 | 1988-09-13 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
| US4873263A (en) | 1985-12-30 | 1989-10-10 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
| JPS62258347A (ja) * | 1986-05-02 | 1987-11-10 | Banyu Pharmaceut Co Ltd | 無水結晶形態のｌ−スレオ−３−（３，４−ジヒドロキシフエニル）−ｎ−メチルセリン |
| ES2042520T3 (es) | 1986-06-10 | 1993-12-16 | Chiesi Farma Spa | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. |
| US4983400A (en) | 1986-06-16 | 1991-01-08 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| DK406686D0 (da) | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
| US5283352A (en) * | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| JPH02138A (ja) | 1987-09-18 | 1990-01-05 | Banyu Pharmaceut Co Ltd | Ｌ‐ドーパ誘導体 |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
| US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5128145A (en) * | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
| US5057321A (en) * | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
| US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
| US5332576A (en) * | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| US5607969A (en) | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| JPH07278076A (ja) * | 1994-04-12 | 1995-10-24 | Ajinomoto Co Inc | Ｌ−フェニルアラニン・モノメチル硫酸塩の晶析方法 |
| US5840756A (en) | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| GB2348371B (en) | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| WO2002028411A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Compounds for sustained release of orally delivered drugs |
| AU2001296703A1 (en) | 2000-10-06 | 2002-04-15 | Xenoport, Inc. | Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism |
| IL159812A0 (en) | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core |
| AU2002340470A1 (en) | 2001-11-13 | 2003-05-26 | Teva Pharmaceutical Industries, Ltd. | L-dopa ethyl ester salts and uses thereof |
| US20030158254A1 (en) | 2002-01-24 | 2003-08-21 | Xenoport, Inc. | Engineering absorption of therapeutic compounds via colonic transporters |
| AU2003293423A1 (en) * | 2002-12-06 | 2004-06-30 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| US20050209181A1 (en) * | 2003-11-05 | 2005-09-22 | Huda Akil | Compositions and methods for diagnosing and treating mental disorders |
| US7323585B2 (en) * | 2004-06-04 | 2008-01-29 | Xenoport, Inc. | Levodopa prodrugs, and compositions and uses thereof |
| RU2365580C2 (ru) * | 2004-06-04 | 2009-08-27 | Ксенопорт, Инк. | Пролекарства леводопа, композиции на их основе и их применения |
| DE102005022276A1 (de) | 2005-05-13 | 2006-11-16 | Ellneuroxx Ltd. | Derivate von Dihydroxyphenylalanin |
| TWI403493B (zh) * | 2005-12-05 | 2013-08-01 | Xenoport Inc | 左旋多巴前藥的甲磺酸鹽，其組成物，及其用途 |
| US9603941B2 (en) | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
| WO2008034087A2 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
| CA2673336A1 (en) * | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| US7829592B2 (en) | 2006-12-21 | 2010-11-09 | Xenoport, Inc. | Catechol protected levodopa diester prodrugs, compositions, and methods of use |
| CN102186804A (zh) * | 2008-10-20 | 2011-09-14 | 克塞诺波特公司 | 合成左旋多巴酯前药的方法 |
| US8399513B2 (en) * | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
| WO2011056240A2 (en) * | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
-
2006
- 2006-12-04 TW TW095144993A patent/TWI403493B/zh not_active IP Right Cessation
- 2006-12-04 ZA ZA200805511A patent/ZA200805511B/xx unknown
- 2006-12-04 EP EP06844799A patent/EP1959948B1/en not_active Not-in-force
- 2006-12-04 KR KR1020087016252A patent/KR101396639B1/ko not_active Expired - Fee Related
- 2006-12-04 US US11/634,354 patent/US7563821B2/en not_active Expired - Fee Related
- 2006-12-04 RU RU2008127312/04A patent/RU2429223C2/ru not_active IP Right Cessation
- 2006-12-04 CA CA2631643A patent/CA2631643C/en not_active Expired - Fee Related
- 2006-12-04 BR BRPI0619425-7A patent/BRPI0619425A2/pt not_active IP Right Cessation
- 2006-12-04 PL PL06844799T patent/PL1959948T3/pl unknown
- 2006-12-04 JP JP2008543539A patent/JP5153641B2/ja not_active Expired - Fee Related
- 2006-12-04 CN CN200680045534XA patent/CN101365439B/zh not_active Expired - Fee Related
- 2006-12-04 ES ES06844799T patent/ES2391575T3/es active Active
- 2006-12-04 NZ NZ569485A patent/NZ569485A/en not_active IP Right Cessation
- 2006-12-04 PT PT06844799T patent/PT1959948E/pt unknown
- 2006-12-04 DK DK06844799.4T patent/DK1959948T3/da active
- 2006-12-04 WO PCT/US2006/046273 patent/WO2007067495A2/en not_active Ceased
- 2006-12-04 AU AU2006322051A patent/AU2006322051B2/en not_active Ceased
-
2008
- 2008-06-04 IL IL191937A patent/IL191937A/en not_active IP Right Cessation
- 2008-06-16 NO NO20082768A patent/NO20082768L/no not_active Application Discontinuation
- 2008-12-31 US US12/347,807 patent/US7968597B2/en not_active Expired - Fee Related
-
2009
- 2009-06-22 US US12/489,146 patent/US7893105B2/en not_active Expired - Fee Related
-
2011
- 2011-01-20 US US13/010,419 patent/US8193242B2/en not_active Expired - Fee Related
-
2012
- 2012-05-16 US US13/473,503 patent/US20120296109A1/en not_active Abandoned
- 2012-09-12 CY CY20121100822T patent/CY1113108T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082768L (no) | Levodopa prodroge mesylat, sammensetninger og anvendelser derav | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2007001918A1 (es) | Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras. | |
| CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
| NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| GT200400239A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| CY1117326T1 (el) | Παραγωγο κατεχολαμινης χρησιμο για τη θεραπεια ασθενειας parkinson | |
| DK2527315T3 (da) | Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom | |
| WO2007100366A3 (en) | Quinolone m1 receptor positive allosteric modulators | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2008002621A3 (en) | Benzyl-substituted quinolone m1 receptor positive allosteric modulators | |
| NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
| DE60314633D1 (de) | Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen | |
| EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
| NZ591873A (en) | Co-crystals of tramadol and nsaids | |
| CL2007001205A1 (es) | Compuestos derivados de n-fenil-3-tio-4-fenil-azetedin-2-ona; procedimiento de preparacion; composicion farmaceutica; combinacion; uso en el tratamiento de una condicion hiperlipidemica, ateroesclerosis, alzheimer y tumores asociados a colesterol | |
| WO2007093450A3 (en) | Deuterated catecholamine derivatives and medicaments comprising said compounds | |
| ATE417607T1 (de) | Sphingolipide gegen krankhafte prozesse in lipid rafts | |
| SG166820A1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2011056240A3 (en) | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use | |
| WO2006099941A8 (de) | Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |